Skip to main navigation Skip to search Skip to main content

COVID-19 and thrombosis: From bench to bedside

Research output: Contribution to journalReview articlepeer-review

167 Scopus citations

Abstract

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite being a respiratory illness, COVID-19 is found to increase the risk of venous and arterial thromboembolic events. Indeed, the link between COVID-19 and thrombosis is attracting attention from the broad scientific community. In this review we will analyze the current available knowledge of the association between COVID-19 and thrombosis. We will highlight mechanisms at both molecular and cellular levels that may explain this association. In addition, the article will review the antithrombotic properties of agents currently utilized or being studied in COVID-19 management. Finally, we will discuss current professional association guidance on prevention and treatment of thromboembolism associated with COVID-19.

Original languageEnglish
Pages (from-to)143-160
Number of pages18
JournalTrends in Cardiovascular Medicine
Volume31
Issue number3
DOIs
StatePublished - Apr 2021

Fingerprint

Dive into the research topics of 'COVID-19 and thrombosis: From bench to bedside'. Together they form a unique fingerprint.

Cite this